Insider Buying: CAMP4 Therapeutics (NASDAQ:CAMP) Director Acquires $27,023.70 in Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Director Richard Young purchased 16,378 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average cost of $1.65 per share, with a total value of $27,023.70. Following the transaction, the director directly owned 186,388 shares in the company, valued at $307,540.20. This trade represents a 9.63% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

CAMP4 Therapeutics Stock Down 5.8%

NASDAQ:CAMP opened at $4.24 on Friday. CAMP4 Therapeutics Corporation has a 52 week low of $1.32 and a 52 week high of $7.75. The company has a fifty day simple moving average of $4.02 and a two-hundred day simple moving average of $4.30. The company has a market cap of $220.18 million, a price-to-earnings ratio of -1.80 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The company had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. On average, analysts expect that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on CAMP shares. Zacks Research lowered CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Chardan Capital set a $6.50 price objective on CAMP4 Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 10th. JPMorgan Chase & Co. upgraded shares of CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $5.00 to $9.00 in a research note on Tuesday, June 16th. Rodman & Renshaw assumed coverage on shares of CAMP4 Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Weiss Ratings downgraded shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.36.

Institutional Trading of CAMP4 Therapeutics

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in shares of CAMP4 Therapeutics during the 2nd quarter worth about $7,185,000. Deutsche Bank AG acquired a new stake in shares of CAMP4 Therapeutics during the 2nd quarter worth about $138,000. Bank of New York Mellon Corp purchased a new stake in CAMP4 Therapeutics during the second quarter worth approximately $365,000. Bank of America Corp DE lifted its stake in CAMP4 Therapeutics by 141,700.0% during the first quarter. Bank of America Corp DE now owns 31,196 shares of the Wireless communications provider’s stock worth $138,000 after purchasing an additional 31,174 shares during the last quarter. Finally, SummitTX Capital L.P. acquired a new position in CAMP4 Therapeutics in the first quarter valued at approximately $1,497,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.